EMP2 and neoplasm: We have previously shown that EMP2 may at least partially serve to increase tumor vascularity through upregulation of VEGF-A within the tumor parenchyma.22 Resistance to bevacizumab is a well-studied topic, with hypoxia-dependent and hypoxia-independent recruitment of alternative kinase signaling pathways,29 changes in autophagy,30,31 and upregulation of alternative promotors of angiogenesis32–38 as potential mechanisms for resistance.